IN Brief:
- Vizient forecasts 2.78% healthcare supply chain inflation from July 2026 to June 2027.
- The sharpest projected increases are in IT hardware and software, medical gases, and facilities-linked services.
- Pharmacy inflation is projected to moderate, shifting budget pressure toward non-clinical categories.
Vizient’s Winter 2026 Spend Management Outlook is forecasting a 2.78% overall increase in healthcare supply chain prices between July 2026 and June 2027, with the organisation highlighting a change that procurement teams will feel quickly: for the first time in more than a decade, pharmacy is no longer projected to be the fastest-growing non-labour expense, as IT and facilities-related costs move to the front of the inflation queue.
The headline number masks a spread of category-level pressures that are likely to land unevenly across providers. Vizient projects pharmacy price growth at 2.84%, down from 3.35% six months earlier, attributing the moderation to increased biosimilar adoption and early impacts associated with the Inflation Reduction Act’s Medicare Drug Price Negotiation Program. That easing is not an all-clear; it is simply a shift in where the steepest increments are expected to appear.
On the non-clinical side, Vizient identifies indirect spend categories and purchased services as the fastest-rising non-labour cost area, led by IT hardware and software with a projected 5.66% increase. The outlook also flags inflation across IT services (4.5%), facilities management (4.13%), construction (3.7%), food (3.63%), and medical gases (5%). In practice, those are categories that tend to be sticky: deferring cybersecurity upgrades, equipment refresh cycles, building maintenance, or compliance-driven spend can carry operational, clinical, and regulatory consequences that outweigh short-term savings.
Vizient’s Carina Dolan, associate vice president for clinical oncology, pharmacoeconomics, and market insights, described the environment as uneven, noting, “This is not a uniform inflation environment,” and pointing to cost pressures that are moderating in some areas while accelerating or shifting elsewhere. For supply chain and procurement leaders, that is a more complicated planning problem than a single inflation index suggests, because it drives budgeting conversations away from broad “price growth” assumptions and toward category-specific trade-offs: capex versus opex, managed services versus in-house capability, and multi-year agreements that can stabilise cost exposure versus shorter renewals that preserve flexibility.
There is also a timing point that matters for contracting. The forecast period begins in July 2026, aligning with budget cycles for many health systems and arriving after several years in which pharma pricing dominated internal narratives around non-labour cost growth. With IT, facilities, construction, and food now carrying a larger share of projected inflation, procurement teams will be pushed to reassess where they apply negotiation intensity, where standardisation programmes are likely to yield returns, and where risk sits if price rises and availability constraints collide.
For the wider supply base, the outlook is another indicator that healthcare cost pressure is shifting beyond clinical product pricing into the enabling infrastructure — digital and physical — that keeps care delivery operating at scale.
